Related Experiment Video
Updated: May 3, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
9.2K
Biostatistic tools in pharmacogenomics--advances, challenges, potential.
Yasunori Sato1, Nan M Laird, Teruhiko Yoshida
1Clinical Research Center, Chiba University of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. yasu@faculty.chiba-u.jp
Current Pharmaceutical Design
|May 13, 2010
Summary
Personalized medicine aims to tailor drug treatments using pharmacogenomics. Biomarkers are crucial for predicting patient response, but their effective use in clinical trials requires careful study design and statistical analysis.
Area of Science:
- Pharmacogenomics and personalized medicine
- Biomarker development and application
- Clinical trial design and statistical analysis
Background:
- Inter-individual drug response variations are common, influenced by host and disease factors.
- These variations affect drug efficacy and safety, impacting pharmacodynamics and pharmacokinetics.
- Current limitations exist in predicting patient response to medications.
Purpose of the Study:
- To review biomarker development, including prognostic vs. predictive markers.
- To discuss study designs for evaluating biomarkers in confirmatory clinical trials.
- To explore statistical methods for biomarker detection in early-phase studies.
Main Methods:
- Review of biomarker development and classification.
- Analysis of study design principles for biomarker evaluation in clinical trials.
- Examination of statistical screening techniques for biomarker discovery.
Main Results:
- Biomarkers can serve as targets, with distinctions between prognostic and predictive roles.
- Optimizing patient selection for therapies relies on effective biomarker evaluation.
- Exploratory statistical methods aid in identifying potential biomarkers.
Conclusions:
- Robust study designs and statistical analyses are essential for pharmacogenomic studies.
- Biomarkers hold promise for personalizing drug therapy and improving patient outcomes.
- Further research is needed to fully leverage biomarkers in clinical practice.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
996
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
996
01:29Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121